Metastases from meningioma are very rare and occur predominantly in WHO grade II and III tumors, with the lungs being the most common site. The increasing use of 68 Ga-DOTA-peptides PET/CT has improved the detection of primary and secondary tumor sites. This imaging modality, evaluating the tumor expression of somatostatin receptors (SSTR), not only refines the diagnostic accuracy but also can guide a subsequent peptide receptor radionuclide therapy (PRRT). We report a case of meningioma brain tumor becoming refractory after initial neurosurgery and stereotactic radiotherapy. Meningioma has progressed to lung metastases displaying high expression of SSTR, and hence suitable for PRRT.
Bekkhoucha et al. (Mon,) studied this question.